Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
[BACKGROUND] The NALLC trial (NCT01441752) demonstrated that postoperative adjuvant chemotherapy combined with traditional Chinese medicine (TCM) improved the quality of life (QoL) and survival in res
- 표본수 (n) 167
- 95% CI .64-1.15
- 추적기간 116.87 months
APA
Wang Y, Jiao L, et al. (2026). Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.. Integrative cancer therapies, 25, 15347354251409081. https://doi.org/10.1177/15347354251409081
MLA
Wang Y, et al.. "Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.." Integrative cancer therapies, vol. 25, 2026, pp. 15347354251409081.
PMID
41589575
Abstract
[BACKGROUND] The NALLC trial (NCT01441752) demonstrated that postoperative adjuvant chemotherapy combined with traditional Chinese medicine (TCM) improved the quality of life (QoL) and survival in resected stage Ib-IIIa non-small-cell lung cancer (NSCLC) patients. This report updates disease-free survival (DFS) and other key outcomes.
[METHODS] Between December 2012 and August 2015, 334 patients were randomized to receive either adjuvant chemotherapy plus traditional Chinese herbal granules (n = 167) or adjuvant chemotherapy plus placebo (n = 167) across 7 centers. Patients continued herbal granules or placebo daily until chemotherapy completion. DFS updates data was conducted in the intention-to-treat (ITT) population.
[RESULTS] The median follow-up was 116.87 months. Median DFS was 71.83 months for the TCM group versus 43.60 months for the control (HR: .86; 95% CI: .64-1.15; = .31). Two-year and 5-year DFS rates were 73.60% and 50.16% for TCM, compared to 67.45% and 44.08% for the control ( = .23). Median overall survival (mOS) was not reached in either group, with 75% OS at 63.40 months for TCM and 53.67 months for the control. Five-year OS rates were 76.15% for TCM and 69.81% for the control ( = .23). Subgroup analysis showed stage Ib patients benefited from TCM in both DFS (HR: .51; = .02) and OS (HR: .34; = .01).
[CONCLUSIONS] Adjuvant chemotherapy combined with TCM showed a potential trend toward improved DFS in early-stage NSCLC patients.
[TRIAL REGISTRATION] This trial was registered with Clinical.
[TRIALS] gov (Number: NCT01441752, July 14, 2011).
[METHODS] Between December 2012 and August 2015, 334 patients were randomized to receive either adjuvant chemotherapy plus traditional Chinese herbal granules (n = 167) or adjuvant chemotherapy plus placebo (n = 167) across 7 centers. Patients continued herbal granules or placebo daily until chemotherapy completion. DFS updates data was conducted in the intention-to-treat (ITT) population.
[RESULTS] The median follow-up was 116.87 months. Median DFS was 71.83 months for the TCM group versus 43.60 months for the control (HR: .86; 95% CI: .64-1.15; = .31). Two-year and 5-year DFS rates were 73.60% and 50.16% for TCM, compared to 67.45% and 44.08% for the control ( = .23). Median overall survival (mOS) was not reached in either group, with 75% OS at 63.40 months for TCM and 53.67 months for the control. Five-year OS rates were 76.15% for TCM and 69.81% for the control ( = .23). Subgroup analysis showed stage Ib patients benefited from TCM in both DFS (HR: .51; = .02) and OS (HR: .34; = .01).
[CONCLUSIONS] Adjuvant chemotherapy combined with TCM showed a potential trend toward improved DFS in early-stage NSCLC patients.
[TRIAL REGISTRATION] This trial was registered with Clinical.
[TRIALS] gov (Number: NCT01441752, July 14, 2011).
MeSH Terms
Humans; Carcinoma, Non-Small-Cell Lung; Female; Male; Chemotherapy, Adjuvant; Drugs, Chinese Herbal; Middle Aged; Lung Neoplasms; Aged; Double-Blind Method; Quality of Life; Disease-Free Survival; Medicine, Chinese Traditional; Adult; Survival Analysis
같은 제1저자의 인용 많은 논문 (5)
- "I wanna look like the person in that picture": Linking selfies on social media to cosmetic surgery consideration based on the tripartite influence model.
- ZmSKIP enhances drought tolerance by reducing stomatal aperture in maize.
- c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.
- Enhancing Node-RADS for preoperative assessment of cervical lymph node metastases in papillary thyroid carcinoma: validation and modification.
- Aging modulation of the immune system and immunotherapy efficacy in cancer.